PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study

Lung cancer is the leading cause of cancer-related deaths worldwide [1, 2]. The prognosis for patients with locally advanced stage III non-small cell lung cancer (NSCLC) remains poor despite the use of modern immunotherapies [3‐5].

One strategy to improve the prognosis is an optimization of tolerability of treatment by more precise irradiation methods [6, 7]. Technological improvements in recent years have enabled dose escalation with better tumor coverage and optimized sparing of normal tissues, resulting in a survival advantage with lower toxicity [8‐10]. These techniques include intensity-modulated radiotherapy, adaptive image-guided radiotherapy and the use of ¹⁸F-FDG PET/CT in radiation planning [11, 12]. In particular, information on metabolism provided by ¹⁸F-FDG PET/CT can improve target volume definition and dose planning before and during radiotherapy (RT), enabling better selection of patients and individualization of therapeutic strategies [13, 14]. A systematic review and meta-analysis could demonstrate a relevant change in target volume definition in about 40% of NSCLC with the use of a planning PET/CT [15]. Accordingly, the multicentric PET-plan study showed a possible isotoxic dose-escalation for the use PET-guided RT [10]. The use of further PET-tracers like FMISO may additionally tailor individual (and possibly smaller) metabolic tumor volumes [16]. However, the reduction of target volume for dose escalation has to be carefully balanced with adequate coverage of the tumor. In the RTOG 0617 trial, high-dose chemo-RT with 74 Gy did result in adverse overall survival (OS) when compared with standard dose RT 60 Gy, the later RT strategy revealing better dose coverage of the target [17, 18].

Despite the new data on the treatment of NSCLC, it is unclear how the radiation planning strategy and the use of PET/CT for radiation planning affect local control and survival. In addition, it is not known when and how often PET/CT should be performed in the setting of chemoradiotherapy and whether it should be performed as staging PET/CT or in the RT planning position. In the present analysis, we evaluated the relevance of ¹⁸F-FDG-PET-based radiotherapy planning on the prognosis of patients with stage III NSCLC in multicenter study including 347 patients.

The study included equal numbers of stage IIIA and IIIB patients (Table 1).

RT was combined with concurrent chemotherapy (CHT) in 250 patients (72.2%), 96 patients (27.8%) received sequential chemoradiotherapy. 75 patients (30%) were treated with combined cisplatin-vinorelbine CHT, 48 (19.2%) carboplatin-vinorelbine, 52 (20.8%) carboplatin-docetaxel, and 75 (30%) other chemotherapy doublet combinations.

In 314 (90.8%) patients’ conventional fractionation was used, compared to 7 (2%) patients were treated with hyperfractionated regimens, and 5 patients (1.5%) undergoing a simultaneous-integrated boost (SIB) concept. 20 patients (5.7%) received other RT concepts.

In analysis of adaptive planning, no significant effect on survival was found for replanned cases when compared to cases with no re-planning (HR = 1.21, 95% CI 0.89–1.64, after covariate adjustment, Fig. 1, Table 1) (Table 2).

In the analysis of PET, cases with PET co-registration showed a similar survival rate as compared to cases without consideration of PET imaging (HR = 0.8, 95% CI 0.56–1.16 after covariate adjustment, Fig. 2, Table 1).

Analyzing centers according to the preferred planning strategy, we found that centers with no preferred method performed worse than those with a predominant planning method (0.62, 95% CI 0.41–0.94, after covariate adjustment, Fig. 3, Table 1). However, this finding is based on only one center in the mixed method group.

The present analysis demonstrates prognostic superiority of a consistent imaging strategy for advanced NSCLC. Our results confirm non-inferiority of target volume reduction in terms of outcome and therefore encourage PET/CT based RT planning for NSCLC.

Our results go along with the findings of Nestle et al. which could show that PET/CT-based reduction of radiotherapy target volume may improve local control without increasing toxicity in patients with locally advanced NSCLC [11]. The correct identification of PET-avid tumor tissue is pivotal as it acts as a starting point for local recurrence: a patterns-of-failure study on NSCLC patients demonstrates local recurrences to occur predominantly within the previous active volume [20].

The multicentric randomized PET-plan study demonstrates the ability of an isotoxic RT dose escalation (mean dose 65.3 Gy vs. 67.3 Gy for the standard vs. the experimental arm) with the use of 18F-FDG PET/CT for planning [10]. Despite smaller target volumes in the PET-arm, locoregional failure was not inferior (30% vs. 17% in the intention-to-treat population after 1 year for the standard vs. experimental arm) [10]. Consistent with our data, no significant impact on OS could be shown. However, a safe RT-volume reduction with improved sparing of healthy lung is likely to results in lower toxicity [21‐23].

As shown previously by our group, we found a mean reduction in GTV volume at the time of re-planning of 48.2 mL or 31.1% [24].

Based on our findings, the consistency of centers in performing each standard, regardless of modality, appears to have a prognostic impact. Patients from centers with no stringently applied RT planning procedure experienced a worse outcome compared to centers with consistent RT planning protocols (CT versus PET/CT). In this respect, it seems advisable not to switch too frequently between different adaptive procedures, but to apply a homogenous in-house protocol.

Although not statistically significant patients with a co-registered PET actually numerically outperformed those with staging PET/CT. This is of importance as planning PET/CT are not mandatory in most studies: in RTOG 0617 around 90% of patients had a PET-staging in each arm, whereas its use for RT-planning was only encouraged [16].

Thus, the use of PET/CT in radiation planning (co-registered or in RT treatment position) should be considered in accordance with modern guidelines (ESTRO-ACROP NSCLC). From a public health perspective the application of PET-based RT planning was shown to be cost-effective when compared to CT-based planning [25]. Other concepts such as simultaneous integrated boost need to take account for altering treatment volumes [26]. As variability in the application of planning techniques might be associated with an adverse survival prospect PET-based planning might additionally contribute to a reduced heterogeneity in the definition of target structures [27].

At the time of enrollment to our study, sequential durvalumab maintenance implemented by the PACIFIC trial was not the standard of care for patients with inoperable stage III NSCLC, but needs to be taken into account today [23]. Importantly, PET/CT staging and treatment planning was not mandatory in the PACIFIC trial but should be considered standard of care based on our findings consistent with recent literature [11, 28]. Since increased lung toxicity has been previously reported in patients treated for stage III NSCLC with durvalumab, reduction of irradiated lung is of increasing importance [29].

From the results of our retrospective study, further direction of future research on RT treatment of patients with locally advanced NSCLC should focus on the possibilities of PET/CT-based RT planning regarding further improvement of local control monitored by PET/CT-based recurrence pattern analyses.

A consistent radiotherapy planning strategy should be followed for patients undergoing definitive chemoradiotherapy for stage III NSCLC. The use of PET/CT-based adaptive radiotherapy planning shows comparable oncologic outcomes and should be considered to avoid radiogenic toxicities.